BiotechTube
Home/Celcuity/David Bridge
DB

David Bridge

Vice President, Quality Assurance and Process Development

Celcuity

Therapeutic Areas

OncologyBreast CancerProstate Cancer

Celcuity Pipeline

DrugIndicationPhase
Gedatolisib + Palbociclib + FulvestrantHR+/HER2- Advanced Breast Cancer (PIK3CA Wild-Type)Phase 3
Gedatolisib + Palbociclib + Letrozole/FulvestrantHR+/HER2- Advanced Breast Cancer (PIK3CA Mutant)Phase 3
Gedatolisib + DarolutamideMetastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 1b/3

Leadership Team at Celcuity

BS
Brian Sullivan
Chief Executive Officer and Co-founder
LL
Lance Laing, PhD
Chief Science Officer and Co-founder
VH
Vicky Hahne
Chief Financial Officer
IG
Igor Gorbatchevsky, MD
Chief Medical Officer
EM
Eldon Mayer
Chief Commercial Officer
BE
Brent Eilefson, JD
General Counsel
BL
Bernhard Lampert, PhD
Vice President, Pharmaceutical Development
NZ
Nadene Zack
Vice President, Clinical Operations
SM
Sunni Miller
Vice President, Regulatory Affairs
FK
Fred Kerwood
Vice President, Program Management
View full Celcuity profile